Shire Returns Blood-Cancer Drug Rights
By

By
Shire, through its Baxalta subsidiary, has returned the worldwide rights for the development and commercialization of the blood-cancer therapeutic, pacritinib, to CTI BioPharma, a Seattle, Washington-based biopharmaceutical company. Baxalta will…

Pfizer, Merck KGaA Partner with Debiopharm on Lung Cancer Drug
By

By
Pfizer and Merck KGaA have formed a collaboration with Debiopharm International, a Lausanne, Switzerland-based biopharmaceutical group of five companies, to evaluate the combination of Debio 1143, Debiopharm’s oral, small-molecule inhibitor…

Novartis Partners for Nanoparticle-Drug Conjugates
By

By
Novartis has formed a collaboration with Cerulean Pharma, a Waltham, Massachusetts-based clinical-stage company developing nanoparticle-drug conjugates (NDCs), to develop NDC product candidates combining Cerulean’s proprietary tumor-targeting technology with Novartis’ proprietary…

AbbVie Opts Out of Arthritis Drug Pact
By

By
AbbVie has decided not to exercise its right to opt-in and license vobarilizumab, an anti-IL-6R nanobody being developed to treat auto-immune disorders by Ablynx, a Ghent, Belgium-based biopharmaceutical company. AbbVie…

Sterinova Launches as New Sterile Injectables Pharma Company
By

By
Sterinova, headquartered in Saint-Hyacinthe, Quebec, Canada, has been launched as a new pharmaceutical company specializing in the development and manufacture of sterile ready-to-use injectable products. The new company is the…

Amgen Invests in Digital Health Company
By

By
Amgen GmbH, a Zug, Switzerland-based affiliate of Amgen, has invested in eHealth Ventures, a Tel Aviv Israel-based digital-health incubator that is comprised of a consortium of organizations and investors active…

Novartis Reports $500 Million in 3Q Procurement Savings
By

By
As part of its third-quarter earnings release, Novartis reported gross savings of approximately $600 million in productivity initiatives in the third quarter, which included $500 million in savings from procurement,…

Allergan Gets US FTC OK for $1.7 Billion Acquisition of Tobira Therapeutics
By

By
Allergan has received US antitrust clearance for its proposed $1.7 billion acquisition of Tobira Therapeutics, a South San Francisco-based clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and…

BASF Suffers Explosion at Site in Ludwigshafen, Germany
By

By
BASF experienced an explosion at its site in Ludwigshafen, Germany, on Monday October 17, 2016. The site is one of the largest chemical complexes globally.  The cause of the explosion…

J&J Opens New Global Services Delivery Center in Tampa
By

By
Johnson & Johnson has opened the new Johnson & Johnson Global Services Delivery Center in Tampa, Florida, which the company first announced in August 2015.  The new 88,500 square-foot building opens…